Tick Insights

Search Icon

Menu Toggle Icon

Skip to content
  • Home
  • Forex
  • CFD Indices
  • CFD Equities
  • Education
  • Events
Tick Insights

Tag: CSPC Pharma

CFD Trading – Buy Chinasoft International (0354.HKE) at $8.56. Stop at $8.03 and Target at $9.50.

January 18, 2022Shueh Ting Wong

CHINASOFT INT’L   Stock Code 0354.HKE

Outlook

Price hit its previous support low at HK$8.05 two days ago, forming potential Double Bottom chart pattern.… Read More

CFD Equities CFD HK Trading Note, CSPC Pharma Leave a comment

CFD Trading – Buy PetroChina (0857.HKE) at $3.95. Stop at $3.73 and Target at $4.20.

January 18, 2022Shueh Ting Wong

PETROCHINA   Stock Code 0857.HKE

Outlook

Price broke and closed above the cloud on 12 Jan 2022, changing the chart outlook to bullish.… Read More

CFD Equities CFD HK Trading Note, CSPC Pharma Leave a comment

CFD Trading – Buy CSPC Pharma (1093.HKE) at $9.30. Stop at $8.70 and Target at $10.20.

January 11, 2022Shueh Ting Wong

CSPC PHARMA   Stock Code 1093.HKE

Outlook

The outlook of the stock price has turned bullish as price broke and closed above the cloud during the last trading session.… Read More

CFD Equities CFD HK Trading Note, CSPC Pharma Leave a comment

About Us

Tick Insights

UTRADE

Upcoming Webinar

US & HK ETF Available For CFD Trade

Stay Connected

Subscribe to this blog and receive notifications of new posts by email.

Like our Facebook page for the latest updates!

 SG UTRADE

Recent Posts

  • FX Commentary – US Dollar Lower On A Poor Set Of U.S. Housing Data
  • CFD Trading – Buy ThaiBev (Y92.SGX) @ $0.690. Stop @ $0.670 and Target @ $0.725.
  • CFD Trading – Buy Hong Fok (H30.SGX) @ $0.915. Stop @ $0.855 and Target @ $1.06.
  • FX Commentary – U.S. Dollar Declined On Improved Risk Appetite.
  • CFD Indices – Wall Street Rallied On Strong US Retail Sales Data

Archives

Disclaimer

This information is prepared by personnel in UOB Kay Hian’s Alternative Products Department and is not the product of UOB Kay Hian’s Research Department. It is not a research report and is not intended as such, although a UOB Kay Hian Research report may be referenced as a link or as an attachment hereto.

Opinions expressed herein may differ from the opinions expressed by other areas of UOB Kay Hian, including research. This commentary is provided for information only. Neither the information nor any views expressed constitutes a solicitation for the purchase or sale of any securities or other financial instruments. It is not a personal recommendation, offer or solicitation to buy or sell.

Scroll to Top
 

Loading Comments...